An observational study in Osteoarthritis and Sarcopenia, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Osteoarthritis by Assiut University — 8 open to participants now, 8 under way, none of them phase 3. Osteoarthritis · Assiut University.
Among the 13 studies in Osteoarthritis by Assiut University, this one is one of 4 that started in 2026, is one of 5 observational ones, and was the 10th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →8 of the 13 studies in Osteoarthritis by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Ages 18–60
Assiut University
Ages 18–70
Assiut University
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
Assiut University
By country, each count listing its studies:
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 224 is above the median of 100 across 602 observational studies indexed under Osteoarthritis.
Median enrollment 60 across the 8 interventional studies, 51 across the 5 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Osteoarthritis by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07566520Assiut UniversityPrevalence of Sarcopenia and Its Associated Factors in Patients With Knee Osteoarthritis in a Tertiary Care Hospital in Upper Egypt | 2027-04 |
| NCT07751263Assiut University15-Hydroxyprostaglandin Dehydrogenase in Osteoarthritis and Ankylosing Spondylitis | 2027-08-02 |
| NCT07784257Assiut UniversityDiagnostic Accuracy of Triphasic Bone Scan and SPECT/CT in Foot and Ankle Osteoarthritis | 2027-08-20 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Osteoarthritis by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Osteoarthritis (OA) and sarcopenia are two highly prevalent, interconnected geriatric syndromes that often coexist, leading to a condition termed "osteosarcopenia". Globally, the pooled prevalence of sarcopenia in patients with knee OA is estimated at approximately 25.07%, significantly higher than in the general population.
Chronic inflammation, joint pain, and reduced physical activity in OA patients create a vicious cycle that accelerates muscle mass loss and functional decline. While international data is robust, Egyptian epidemiological data remains limited. Recent studies in Egypt have identified a high risk of sarcopenia among older adults with fragility fractures and a prevalence of 17.7% in nursing home residents. However, targeted data on the OA population in Egypt is still lacking. Current management in Egyptian primary care centers primarily focuses on symptomatic relief of OA through analgesics and physical therapy. Sarcopenia often remains underdiagnosed because routine screening tools, such as the SARC-F questionnaire or Bioelectrical Impedance Analysis (BIA), are not yet integrated into standard family medicine protocols. This oversight leads to increased frailty and poorer surgical outcomes for patients requiring joint replacement. In the family medicine practice, identifying sarcopenia early is vital for holistic care. Understanding the local prevalence and risk factors-such as Vitamin D deficiency, sedentary behavior, and low protein intake-is essential to tailor interventions. This research aims to provide the evidentiary basis for incorporating sarcopenia screening into primary care OA management, ultimately improving patient mobility and quality of life
Adult patients aged 40 years and older, diagnosed with knee osteoarthritis, who are attending the Assiut University Trauma Hospital.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 40 years and older diagnosed with knee osteoarthritis based on the American College of Rheumatology (ACR) criteria attending the Assiut University Trauma Hospital.
Prevalence of sarcopenia in knee osteoarthritis patients
Prevalence of OA patients who meet the diagnostic criteria for sarcopenia (low muscle mass, strength, and physical performance) according to the European Working Group on Sarcopenia in Older People (EWGSOP2) revised consensus.
Time frame: at baseline
Nutritional Risk Assessment via Malnutrition Universal Screening Tool (MUST)
Evaluation of nutritional status as a factor associated with sarcopenia. The MUST score is a five-step screening tool with a total score ranging from 0 (low risk) to 2 or more (high risk).
Time frame: Baseline
The Quality of Life Factor (EQ-5D Index)
Assessment of the impact of sarcopenia and OA on quality of life. The 5 dimensions (Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression)
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Apr 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.